Ifinatamab Deruxtecan (I-DXd)

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Extensive-stage Small-cell Lung Cancer

Conditions

Extensive-stage Small-cell Lung Cancer

Trial Timeline

Mar 9, 2022 → Dec 15, 2026

NCT ID

NCT05280470

About Ifinatamab Deruxtecan (I-DXd)

Ifinatamab Deruxtecan (I-DXd) is a phase 2 stage product being developed by Daiichi Sankyo for Extensive-stage Small-cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05280470. Target conditions include Extensive-stage Small-cell Lung Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05280470	Phase 2	Active	Mar 9, 2022	Dec 15, 2026	Extensive-stage Small-cell Lung Cancer
NCT04145622	Phase 1/2	Recruiting	Nov 3, 2019	Oct 31, 2029	Advanced Solid Tumor

Competing Products

20 competing products in Extensive-stage Small-cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
Valemetostat + Atezolizumab	Daiichi Sankyo	Phase 1	33
SHR-1316 + Carboplatin + Etoposide + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Neoantigen DNA vaccine + Durvalumab	AstraZeneca	Phase 2	52
Etoposide with Carboplatin or Cisplatin + Durvalumab	AstraZeneca	Phase 2	52
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin	AstraZeneca	Phase 1	33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparib	AstraZeneca	Phase 2	52
Durvalumab + Cisplatin + Carboplatin + Etoposide	AstraZeneca	Phase 3	77
Atezolizumab 1200 mg in 20 ML Injection + ADC Vaccine + Carboplatin	Roche	Phase 1/2	41
Tarlatamab + Durvalumab	Amgen	Phase 3	76
Carfilzomib + Carboplatin + Etoposide	Amgen	Phase 1/2	40
Tafolecimab + Sintilimab (approved) + Etoposide + Carboplatin / Cisplatin	Innovent Biologics	Phase 2	51
Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)	Bristol Myers Squibb	Phase 3	76
BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + Etoposide	Bristol Myers Squibb	Phase 3	76
BMS-986012 + Carboplatin + Etoposide + Nivolumab	Bristol Myers Squibb	Phase 2	51
Ivonescimab + Cadonilimab + AK117 + Etoposide + Carboplatin (AUC 5)	Akeso	Phase 2	51
Teniposide administration	China Resources Pharmaceutical Group	Phase 2	49
BNT327 Dose Level 1 (DL1) + BNT327 Dose Level 2 (DL2) + Etoposide + Carboplatin + Paclitaxel + Topotecan	BioNTech	Phase 2	49
Zepzelca	Jazz Pharmaceuticals	Pre-clinical	20
Lurbinectedin + Durvalumab	Jazz Pharmaceuticals	Phase 2	49
Surufatinib + Anti-PD-1/L1	HUTCHMED	Phase 2	47

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved